DRKS00031563招募中不适用
Outcomes of FIrst and possibility of REdo-TAVI with different transcatheter heart valves - FIRE TAVI
Deutsches Herzzentrum der Charité0 个研究点目标入组 260 人开始时间: 2023年3月27日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 260
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Patients with aortic regurgitation or stenosis and performed TAVI (01.01.2018-30.09.2022)
排除标准
- 未提供
研究者
相似试验
招募中
不适用
VANTAGE Trial: Evaluation of TAVR using the NAVITOR* valve in a global investigatioAortic valve replacementHeartfailure10046973NL-OMON51939Abbott Medical Nederland30
已完成
不适用
A phase II study for the safety and efficacy of TAS-102 and Bevacizumab for patients with unresectable colorectal cancer considering Oxaliplatin to stop and go.unresectable colorectal cancerJPRN-UMIN000022535Gunma University45
进行中（未招募）
1 期
This is a multicenter, double-blind, randomized, placebo-controlled, parallel-group study.The efficacy and safety of investigated drug RVT-101 at a dose of 35 mg daily when used as an adjunct treatment to stable donepezil therapy will be evaluated over a 24-week treatment period for mild to moderate Alzheimer’s disease in patients on stable therapy with donepezil.Alzheimer’s DiseaseMedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2015-002957-37-SKAxovant Sciences Ltd.1,150
进行中（未招募）
1 期
This is a multicenter, double-blind, randomized, placebo-controlled, parallel-group study.The efficacy and safety of investigated drug RVT-101 at a dose of 35 mg daily when used as an adjunct treatment to stable donepezil therapy will be evaluated over a 24-week treatment period for mild to moderate Alzheimer’s disease in patients on stable therapy with donepezil.Alzheimer’s DiseaseMedDRA version: 19.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2015-002957-37-BGAxovant Sciences Ltd.1,150
进行中（未招募）
1 期
This is a multicenter, double-blind, randomized, placebo-controlled, parallel-group study.The efficacy and safety of investigated drug RVT-101 at a dose of 35 mg daily when used as an adjunct treatment to stable donepezil therapy will be evaluated over a 24-week treatment period for mild to moderate Alzheimer’s disease in patients on stable therapy with donepezil.Alzheimer’s DiseaseMedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2015-002957-37-ITAXOVANT SCIENCES LTD.1,315